SNSE

$30.01

Pre-MarketAs of Mar 17, 8:00 PM UTC

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Recent News

Pharmaceutical Technology
Oct 31, 2025

Sensei to ditch its lead candidate and cut workforce amidst strategic review

The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.